Cargando…

Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma

BACKGROUND: Numerous studies across a variety of malignancies have demonstrated that health insurance status is associated with differences in clinical presentation, type of treatments received, and survival. The effect of insurance status on the management of soft tissue sarcoma is unknown. We asse...

Descripción completa

Detalles Bibliográficos
Autores principales: Jain, Varsha, Venigalla, Sriram, Sebro, Ronnie A., Karakousis, Giorgos C., Wilson, Robert J., Weber, Kristy L., Shabason, Jacob E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797574/
https://www.ncbi.nlm.nih.gov/pubmed/31483578
http://dx.doi.org/10.1002/cam4.2441
_version_ 1783459857645436928
author Jain, Varsha
Venigalla, Sriram
Sebro, Ronnie A.
Karakousis, Giorgos C.
Wilson, Robert J.
Weber, Kristy L.
Shabason, Jacob E.
author_facet Jain, Varsha
Venigalla, Sriram
Sebro, Ronnie A.
Karakousis, Giorgos C.
Wilson, Robert J.
Weber, Kristy L.
Shabason, Jacob E.
author_sort Jain, Varsha
collection PubMed
description BACKGROUND: Numerous studies across a variety of malignancies have demonstrated that health insurance status is associated with differences in clinical presentation, type of treatments received, and survival. The effect of insurance status on the management of soft tissue sarcoma is unknown. We assessed the association of insurance on (a) stage at diagnosis, (b) receipt of neoadjuvant/adjuvant radiation therapy, and (c) overall survival (OS) in patients with soft tissue sarcoma. METHODS: The study cohort was identified from the National Cancer Database (NCDB) and consisted of patients with stage I‐IV soft tissue sarcoma of various histologies diagnosed from 2004 to 2015. The patients were stratified by age (<65 and ≥65 years) and by insurance status (commercial, Medicare, Medicaid and uninsured). Using multivariable logistic regression analysis, we evaluated the association between insurance status and (a) stage at diagnosis (Stage I‐III vs IV), and (b) receipt of neoadjuvant/adjuvant radiation therapy in patients with locally advanced disease. The association of insurance status on OS was assessed using Kaplan‐Meier and multivariable Cox proportional hazards analyses. A propensity score matched survival analysis was performed to account for measured confounders. RESULTS: 49 754 patients were identified of whom 23 677 (48%) had commercial insurance, 20 867 (42%) had Medicare, 3229 (6%) had Medicaid, and 1981 (4%) were uninsured. In patients <65 years, those with Medicaid (OR = 1.74, 95% CI: 1.57‐1.93, P < .001) and the uninsured (OR = 1.71, 95% CI: 1.51‐1.94, P < .001) were more likely to present with stage IV vs Stage I‐III disease. Furthermore, among patients with locally advanced disease treated with limb sparing surgery, those with Medicaid (OR = 0.87, 95% CI: 0.77‐ 0.98, P = .021) and the uninsured (OR = 0.73, 95% CI: 0.63‐0.85, P < .001) were less likely to receive neoadjuvant or adjuvant radiotherapy as compared to those with commercial insurance. Lastly, having Medicaid (HR = 1.26, 95% CI: 1.17‐1.34, P < .001) and no insurance (HR = 1.30, 95% CI: 1.20‐1.41, P < .001) was associated with worse OS compared to having commercial insurance, a finding which remained significant after propensity score matching. In contrast, in patients ≥65 years, there were no statistically significant differences between those with Medicare and commercial insurance with regards to disease presentation, receipt of radiotherapy, or survival. CONCLUSIONS: In a large modern cohort identified from the NCDB, commercial insurance status in patients <65 years was associated early diagnosis, receipt of neoadjuvant/adjuvant radiation therapy, and overall survival for patients with soft tissue sarcoma. Further efforts are warranted to understand disparities in care based on health insurance in the United States.
format Online
Article
Text
id pubmed-6797574
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67975742019-10-21 Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma Jain, Varsha Venigalla, Sriram Sebro, Ronnie A. Karakousis, Giorgos C. Wilson, Robert J. Weber, Kristy L. Shabason, Jacob E. Cancer Med Clinical Cancer Research BACKGROUND: Numerous studies across a variety of malignancies have demonstrated that health insurance status is associated with differences in clinical presentation, type of treatments received, and survival. The effect of insurance status on the management of soft tissue sarcoma is unknown. We assessed the association of insurance on (a) stage at diagnosis, (b) receipt of neoadjuvant/adjuvant radiation therapy, and (c) overall survival (OS) in patients with soft tissue sarcoma. METHODS: The study cohort was identified from the National Cancer Database (NCDB) and consisted of patients with stage I‐IV soft tissue sarcoma of various histologies diagnosed from 2004 to 2015. The patients were stratified by age (<65 and ≥65 years) and by insurance status (commercial, Medicare, Medicaid and uninsured). Using multivariable logistic regression analysis, we evaluated the association between insurance status and (a) stage at diagnosis (Stage I‐III vs IV), and (b) receipt of neoadjuvant/adjuvant radiation therapy in patients with locally advanced disease. The association of insurance status on OS was assessed using Kaplan‐Meier and multivariable Cox proportional hazards analyses. A propensity score matched survival analysis was performed to account for measured confounders. RESULTS: 49 754 patients were identified of whom 23 677 (48%) had commercial insurance, 20 867 (42%) had Medicare, 3229 (6%) had Medicaid, and 1981 (4%) were uninsured. In patients <65 years, those with Medicaid (OR = 1.74, 95% CI: 1.57‐1.93, P < .001) and the uninsured (OR = 1.71, 95% CI: 1.51‐1.94, P < .001) were more likely to present with stage IV vs Stage I‐III disease. Furthermore, among patients with locally advanced disease treated with limb sparing surgery, those with Medicaid (OR = 0.87, 95% CI: 0.77‐ 0.98, P = .021) and the uninsured (OR = 0.73, 95% CI: 0.63‐0.85, P < .001) were less likely to receive neoadjuvant or adjuvant radiotherapy as compared to those with commercial insurance. Lastly, having Medicaid (HR = 1.26, 95% CI: 1.17‐1.34, P < .001) and no insurance (HR = 1.30, 95% CI: 1.20‐1.41, P < .001) was associated with worse OS compared to having commercial insurance, a finding which remained significant after propensity score matching. In contrast, in patients ≥65 years, there were no statistically significant differences between those with Medicare and commercial insurance with regards to disease presentation, receipt of radiotherapy, or survival. CONCLUSIONS: In a large modern cohort identified from the NCDB, commercial insurance status in patients <65 years was associated early diagnosis, receipt of neoadjuvant/adjuvant radiation therapy, and overall survival for patients with soft tissue sarcoma. Further efforts are warranted to understand disparities in care based on health insurance in the United States. John Wiley and Sons Inc. 2019-09-04 /pmc/articles/PMC6797574/ /pubmed/31483578 http://dx.doi.org/10.1002/cam4.2441 Text en © 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Cancer Research
Jain, Varsha
Venigalla, Sriram
Sebro, Ronnie A.
Karakousis, Giorgos C.
Wilson, Robert J.
Weber, Kristy L.
Shabason, Jacob E.
Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma
title Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma
title_full Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma
title_fullStr Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma
title_full_unstemmed Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma
title_short Association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma
title_sort association of health insurance status with presentation, treatment and outcomes in soft tissue sarcoma
topic Clinical Cancer Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6797574/
https://www.ncbi.nlm.nih.gov/pubmed/31483578
http://dx.doi.org/10.1002/cam4.2441
work_keys_str_mv AT jainvarsha associationofhealthinsurancestatuswithpresentationtreatmentandoutcomesinsofttissuesarcoma
AT venigallasriram associationofhealthinsurancestatuswithpresentationtreatmentandoutcomesinsofttissuesarcoma
AT sebroronniea associationofhealthinsurancestatuswithpresentationtreatmentandoutcomesinsofttissuesarcoma
AT karakousisgiorgosc associationofhealthinsurancestatuswithpresentationtreatmentandoutcomesinsofttissuesarcoma
AT wilsonrobertj associationofhealthinsurancestatuswithpresentationtreatmentandoutcomesinsofttissuesarcoma
AT weberkristyl associationofhealthinsurancestatuswithpresentationtreatmentandoutcomesinsofttissuesarcoma
AT shabasonjacobe associationofhealthinsurancestatuswithpresentationtreatmentandoutcomesinsofttissuesarcoma